These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 29132538)

  • 1. Immunometabolic profiling of T cells from patients with relapsing-remitting multiple sclerosis reveals an impairment in glycolysis and mitochondrial respiration.
    La Rocca C; Carbone F; De Rosa V; Colamatteo A; Galgani M; Perna F; Lanzillo R; Brescia Morra V; Orefice G; Cerillo I; Florio C; Maniscalco GT; Salvetti M; Centonze D; Uccelli A; Longobardi S; Visconti A; Matarese G
    Metabolism; 2017 Dec; 77():39-46. PubMed ID: 29132538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immuno-metabolic impact of the multiple sclerosis patients' sera on endothelial cells of the blood-brain barrier.
    Sheikh MH; Henson SM; Loiola RA; Mercurio S; Colamatteo A; Maniscalco GT; De Rosa V; McArthur S; Solito E
    J Neuroinflammation; 2020 May; 17(1):153. PubMed ID: 32386505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects.
    Klotz L; Eschborn M; Lindner M; Liebmann M; Herold M; Janoschka C; Torres Garrido B; Schulte-Mecklenbeck A; Gross CC; Breuer J; Hundehege P; Posevitz V; Pignolet B; Nebel G; Glander S; Freise N; Austermann J; Wirth T; Campbell GR; Schneider-Hohendorf T; Eveslage M; Brassat D; Schwab N; Loser K; Roth J; Busch KB; Stoll M; Mahad DJ; Meuth SG; Turner T; Bar-Or A; Wiendl H
    Sci Transl Med; 2019 May; 11(490):. PubMed ID: 31043571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of Regulatory T-Cells in Multiple Sclerosis Patients Treated with Interferon Beta-1a.
    Ebrahimimonfared M; Ganji A; Zahedi S; Nourbakhsh P; Ghasami K; Mosayebi G
    CNS Neurol Disord Drug Targets; 2018; 17(2):113-118. PubMed ID: 29589548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.
    Goldberg LD; Edwards NC; Fincher C; Doan QV; Al-Sabbagh A; Meletiche DM
    J Manag Care Pharm; 2009 Sep; 15(7):543-55. PubMed ID: 19739877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioenergetics profile of CD4(+) T cells in relapsing remitting multiple sclerosis subjects.
    De Riccardis L; Rizzello A; Ferramosca A; Urso E; De Robertis F; Danieli A; Giudetti AM; Trianni G; Zara V; Maffia M
    J Biotechnol; 2015 May; 202():31-9. PubMed ID: 25701681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD28 Autonomous Signaling Up-Regulates C-Myc Expression and Promotes Glycolysis Enabling Inflammatory T Cell Responses in Multiple Sclerosis.
    Kunkl M; Sambucci M; Ruggieri S; Amormino C; Tortorella C; Gasperini C; Battistini L; Tuosto L
    Cells; 2019 Jun; 8(6):. PubMed ID: 31212712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relapse outcomes, safety, and treatment patterns in patients diagnosed with relapsing-remitting multiple sclerosis and initiated on subcutaneous interferon β-1a or dimethyl fumarate: a real-world study.
    Ernst FR; Barr P; Elmor R; Wong SL
    Curr Med Res Opin; 2017 Dec; 33(12):2099-2106. PubMed ID: 28906152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunometabolic profiling of patients with multiple sclerosis identifies new biomarkers to predict disease activity during treatment with interferon beta-1a.
    Lanzillo R; Carbone F; Quarantelli M; Bruzzese D; Carotenuto A; De Rosa V; Colamatteo A; Micillo T; De Luca Picione C; Saccà F; De Rosa A; Moccia M; Brescia Morra V; Matarese G
    Clin Immunol; 2017 Oct; 183():249-253. PubMed ID: 28823971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
    Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
    Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alemtuzumab for multiple sclerosis.
    Riera R; Porfírio GJ; Torloni MR
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD011203. PubMed ID: 27082500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered Immune Phenotypes and
    Devi-Marulkar P; Moraes-Cabe C; Campagne P; Corre B; Meghraoui-Kheddar A; Bondet V; Llibre A; Duffy D; Maillart E; Papeix C; Pellegrini S; Michel F
    Front Immunol; 2021; 12():628375. PubMed ID: 34113337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis.
    Hamamcioglu K; Reder AT
    Mult Scler; 2007 May; 13(4):459-70. PubMed ID: 17463069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal assessment of immuno-metabolic parameters in multiple sclerosis patients during treatment with glatiramer acetate.
    Carrieri PB; Carbone F; Perna F; Bruzzese D; La Rocca C; Galgani M; Montella S; Petracca M; Florio C; Maniscalco GT; Spitaleri DL; Iuliano G; Tedeschi G; Della Corte M; Bonavita S; Matarese G
    Metabolism; 2015 Sep; 64(9):1112-21. PubMed ID: 25986733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-29b variants and MxA expression change during interferon beta therapy in patients with relapsing-remitting multiple sclerosis.
    Fattahi M; Rezaei N; Nematalahi FS; Shaygannejad V; Fouladi S; Karimi L; Fathi F; Dehghani L; Mirmosayyeb O; Eskandari N
    Mult Scler Relat Disord; 2019 Oct; 35():241-245. PubMed ID: 31421628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relapsing-Remitting Multiple Sclerosis Is Characterized by a T Follicular Cell Pro-Inflammatory Shift, Reverted by Dimethyl Fumarate Treatment.
    Cunill V; Massot M; Clemente A; Calles C; Andreu V; Núñez V; López-Gómez A; Díaz RM; Jiménez MLR; Pons J; Vives-Bauzà C; Ferrer JM
    Front Immunol; 2018; 9():1097. PubMed ID: 29896193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Expression Levels of miR-29b-3p and miR-326 in T Helper-1 and T Helper-17 Cells Isolated from Responsive and Non-responsive Relapsing-remitting Multiple Sclerosis Patients Treated with Interferon-beta.
    Karimi L; Eskandari N; Shaygannejad V; Zare N; Andalib A; Khanahmad H; Mirmosayyeb O
    Iran J Allergy Asthma Immunol; 2020 Aug; 19(4):416-425. PubMed ID: 33463108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monocyte and Lymphocyte Activation and Regulation in Multiple Sclerosis Patients. Therapy Effects.
    González-Oria MC; Márquez-Coello M; Girón-Ortega JA; Argente J; Moya M; Girón-González JA
    J Neuroimmune Pharmacol; 2019 Sep; 14(3):413-422. PubMed ID: 30649665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study.
    Benedict RH; Cohan S; Lynch SG; Riester K; Wang P; Castro-Borrero W; Elkins J; Sabatella G
    Mult Scler; 2018 May; 24(6):795-804. PubMed ID: 28485186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.